3 Fermentation Based Biopharma Company, Specialty Pharma Company and Advanced Pharma Intermediates Maker Stocks With a Strong Future Roadmap: Concord Biotech, Ajanta Pharma and Acutaas Chemicals
- October 30, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Concord Biotech, Ajanta Pharma and Acutaas Chemicals: ROE of 12.9% to 23.3% and FY22 to FY26 revenue CAGR of 10.7% to 27.5%. Prices as of 29 Oct 2026.
Quick Answer
The three fermentation drug and specialty pharma stocks to watch are Concord Biotech, Ajanta Pharma and Acutaas Chemicals. Their return on equity ranges from 12.9% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.7% to 27.5%. Ajanta Pharma has the highest return on equity at 23.3%, while Acutaas Chemicals has the fastest revenue growth at 27.5% a year. Prices are based on the 29 October 2026 close, and this article is educational, not investment advice.
Fermentation drug and specialty pharma stocks give investors a way to track businesses that sit close to everyday demand in India. Concord Biotech, Ajanta Pharma and Acutaas Chemicals cover a fermentation based biopharma company, a specialty pharma company and an advanced pharma intermediates maker.
This list covers three fermentation drug and specialty pharma stocks with complete current figures: Concord Biotech, Ajanta Pharma and Acutaas Chemicals. Every figure comes from the latest reported financials and the 29 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Fermentation Drug and Specialty Pharma Stocks?
Fermentation drug and specialty pharma stocks are listed companies that make oncology and immunosuppressant ingredients through fermentation, sell specialty medicines in India and overseas and supply advanced intermediates to pharma and battery makers. Their earnings depend on export orders, approvals and product mix.
Fermentation Drug and Specialty Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Concord Biotech | 1,230.6 | 13,421 | 49.2 | 36.0 | 12.9 | 0.00 |
| Ajanta Pharma | 3,459.7 | 41,241 | 36.3 | 36.0 | 23.3 | 0.06 |
| Acutaas Chemicals | 3,976.7 | 31,066 | 70.8 | 36.2 | 21.5 | 0.02 |
On valuation, all three trade at a P/E above their industry P/E, which reflects the growth the market already expects from them. Readers comparing fermentation drug and specialty pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Fermentation Drug and Specialty Pharma Stocks Have a Strong Roadmap in India?
Fermentation drug and specialty pharma stocks have a strong roadmap in India because global drug makers adding Indian suppliers, steady specialty medicine demand and new uses for advanced chemistry keep widening the market for these companies.
- Global supply. Overseas drug makers add Indian partners.
- Specialty care. Focused medicines support better earnings quality.
- Advanced chemistry. Intermediates serve pharma and batteries.
Why Concord Biotech Features Among These Fermentation Drug and Specialty Pharma Stocks
Among the fermentation drug and specialty pharma stocks on this list, Concord Biotech is a Gujarat-based biopharma company that makes fermentation-based active ingredients such as immunosuppressants, oncology drugs and anti-infectives for global pharma customers.
In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%.
Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0.
Roadmap: The company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.
What to watch: Monitor the pace of new product introductions and the contribution from formulations.
Why Ajanta Pharma Features Among These Fermentation Drug and Specialty Pharma Stocks
Among the pharma and chemistry exporters shares on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.
The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0.
Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore.
Roadmap: The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.
What to watch: Monitor the pace of new launches in branded markets and the momentum in the United States generics business.
Why Acutaas Chemicals Features Among These Fermentation Drug and Specialty Pharma Stocks
Among the three companies on this list, Acutaas Chemicals, earlier known as Ami Organics, is a Surat-based speciality chemicals company that makes advanced pharmaceutical intermediates, battery electrolyte additives and active ingredients for global customers.
Revenue rose from Rs 523 crore in FY22 to Rs 1,381 crore in FY26, a compound annual growth rate of 27.5%. Net profit grew from Rs 72.0 crore in FY22 to Rs 356 crore in FY26, which works out to a compound annual growth rate of 49.2%.
The company has a return on equity of 21.5%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 31,066 crore. The stock trades at a P/E of 70.8, above the industry P/E of 36.2.
Roadmap: The company is expanding its range of advanced intermediates and building new capacity for battery materials and innovator pharma supply. Long-term supply relationships with global customers support its order flow.
What to watch: Follow capacity additions, new product approvals and export orders.
Concord Biotech vs Ajanta Pharma vs Acutaas Chemicals on Key Financials
The table below sets the three fermentation drug and specialty pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Concord Biotech | 736 | 1,107 | 10.7% | 259 | 23.4% |
| Ajanta Pharma | 3,457 | 5,625 | 12.9% | 1,056 | 18.8% |
| Acutaas Chemicals | 523 | 1,381 | 27.5% | 356 | 25.8% |
Ajanta Pharma posts the highest return on equity in this group at 23.3%. Ajanta Pharma has the largest FY26 revenue at Rs 5,625 crore, and Acutaas Chemicals shows the fastest revenue growth with a 27.5% compound annual rate. A useful habit with fermentation drug and specialty pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Fermentation Drug and Specialty Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these fermentation drug and specialty pharma stocks, the main points are: Long-term pharma and chemistry exporters shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Currency moves. Export earnings move with the rupee.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter fermentation drug and specialty pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Fermentation Drug and Specialty Pharma Stocks
Fermentation drug and specialty pharma stocks work best when investors track growth, valuation and return on equity side by side. Concord Biotech, Ajanta Pharma and Acutaas Chemicals each have a clear plan to grow. Based on the 29 October 2026 close, Concord Biotech trades at Rs 1,230.6, Ajanta Pharma at Rs 3,459.7 and Acutaas Chemicals at Rs 3,976.7. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these fermentation drug and specialty pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track fermentation drug and specialty pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are fermentation drug and specialty pharma stocks?
Ans. Fermentation drug and specialty pharma stocks are listed companies that make oncology and immunosuppressant ingredients through fermentation, sell specialty medicines in India and overseas and supply advanced intermediates to pharma and battery makers. Their earnings depend on export orders, approvals and product mix. This list looks at three of them, Concord Biotech, Ajanta Pharma and Acutaas Chemicals, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.
Which fermentation drug and specialty pharma stocks are covered in this list?
Ans. This list covers Concord Biotech, Ajanta Pharma and Acutaas Chemicals. Based on the 29 October 2026 close, Concord Biotech traded at Rs 1,230.6, Ajanta Pharma at Rs 3,459.7 and Acutaas Chemicals at Rs 3,976.7. Their return on equity ranges from 12.9% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.7% to 27.5%.
Why do fermentation drug and specialty pharma stocks have a strong future roadmap in India?
Ans. Fermentation drug and specialty pharma stocks have a strong roadmap in India because global drug makers adding Indian suppliers, steady specialty medicine demand and new uses for advanced chemistry keep widening the market for these companies. The main drivers are as follows. Global supply. Overseas drug makers add Indian partners. Specialty care. Focused medicines support better earnings quality. Advanced chemistry. Intermediates serve pharma and batteries. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Concord Biotech performed financially?
Ans. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.
How has Ajanta Pharma performed financially?
Ans. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.
How has Acutaas Chemicals performed financially?
Ans. Revenue rose from Rs 523 crore in FY22 to Rs 1,381 crore in FY26, a compound annual growth rate of 27.5%. Net profit grew from Rs 72.0 crore in FY22 to Rs 356 crore in FY26, which works out to a compound annual growth rate of 49.2%. The company has a return on equity of 21.5%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 31,066 crore. The stock trades at a P/E of 70.8, above the industry P/E of 36.2. Looking ahead, the company is expanding its range of advanced intermediates and building new capacity for battery materials and innovator pharma supply. Long-term supply relationships with global customers support its order flow.
What risks should investors check before buying fermentation drug and specialty pharma stocks?
Ans. Investors should check a few risks before buying fermentation drug and specialty pharma stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of fermentation drug and specialty pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.